Pediatric Clinics of North America - CIPERJ

354 ADAMS & WENTZEL
[22] Kasabach H, Merritt K. Capillary hemangioma with extensive purpura: report of a case.
Am J Dis Child 1940;59:1063–70.
[23] Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy
(Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma
and not with common infantile hemangioma. Plast Reconstr Surg 1997;100(6):1377–86.
[24] Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not
have ‘‘true’’ hemangiomas. J Pediatr 1997;130(4):631–40.
[25] Gruman A, Liang MG, Mulliken JB, et al. Kaposiform hemangioendothelioma without
Kasabach-Merritt phenomenon. J Am Acad Dermatol 2005;52(4):616–22.
[26] Haisley-Royster C, Enjolras O, Freden JJ, et al. Kasabach-merritt phenomenon: a retrospective
study of treatment with vincristine. J Pediatr Hematol Oncol 2002;24(6):459–62.
[27] Mulliken JB, Anupindi S, Ezekowitz RAB, et al. Case 13-2004: a newborn girl with a large
cutaneous lesion, thrombocytopenia, and anemia. N Engl J Med 2004;350:1764–75.
[28] Hauer J, Graubner U, Konstantopoulos N, et al. Effective treatment of kaposiform hemangioendotheliomas
associated with Kasabach-Merritt phenomenon using four-drug regimen.
Pediatr Blood Cancer 2007;49(6):852–4.
[29] Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Merritt phenomenon
in 41 patients. J Am Acad Dermatol 2000;42:225–35.
[30] Adams D. Hemangioma and vascular malformations center. Available at: http://www.
cincinnatichildrens.org/svc/alpha/h/vascular. Accessed March 11, 2008.
[31] Enjolras O, Riche MC, Merland JJ, et al. Management of alarming hemangiomas in infancy:
a review of 25 cases. Pediatrics 1990;85(4):491–8.
[32] Bartoshesky LE, Bull M, Ferngold M. Corticosteroid treatment of cutaneous hemangiomas:
how effective A report on 24 children. Clin Pediatr (Phila) 1978;17(8):625, 629–38.
[33] Brown SH Jr, Neerhout RC, Fonkalsrud EW. Prednisone therapy in the management of
large hemangiomas in infants and children. Surgery 1972;71(2):168–73.
[34] Hasan Q, Tan ST, Gush J, et al. Steroid therapy of a proliferating hemangioma: histochemical
and molecular changes. Pediatrics 2000;105:117–20.
[35] Maronn ML, Corden T, Drolet BA. Pneumocystis carinii pneumonia in infant treated with
oral steroids for hemangioma. Arch Dermatol 2007;143(9):1224–5.
[36] Boon LM, MacDonald DM, Muliken JB. Complications of systemic corticosteroid therapy
for problematic hemangioma. Plast Reconstr Surg 1999;104(6):1616–23.
[37] Adams DM. The nonsurgical management of vascular lesions. Facial Plast Surg Clin North
Am 2001;9:601–8.
[38] Adams DM, Orme L, Bowers D. Vincristine treatment of complicated hemangiomas. 14th
International Workshop on Vascular Anomalies, Netherlands, June 2002.
[39] Enjolras O, Breviere GM, Roger G, et al. Vincristine treatment for function- and life-threatening
infantile hemangioma. Arch Pediatr 2004;11:99–107.
[40] Fawcett SL, Grant I, Hall PN, et al. Vincristine as a treatment for a large haemangioma
threatening vital functions. Br J Plast Surg 2004;57(2):168–71.
[41] Perez-Valle S, Peinador M, Herraiz P, et al. Vincristine, an efficacious alternative for diffuse
neonatal haemangiomatosis. Acta Paediatr 2007; [epub ahead of print].
[42] Ezekowitz R, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas
of infancy. N Engl J Med 1992;326(22):1456–63.
[43] Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b.
J Pediatr Hematol Oncol 1997;19(3):237–44.
[44] Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of
interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998;132(3 Pt 1):
527–30.
[45] Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances
in infants receiving interferon-alpha. Laryngoscope 2004;114(7):1231–6.
[46] List AF. Lenalidomidedthe phoenix rises. N Engl J Med 2007;357(21):2183–6.